18 results about "Fluticasone" patented technology

The invention discloses a method for detecting the granularity of raw materials in a suspension for fluticasone propionate aerosol inhalation, which comprises the following steps: heating the suspension for fluticasone propionate aerosol inhalation to be detected, and dissolving auxiliary materials to obtain a solution only containing the raw materials; adding the obtained solution into a heat-insulating dispersing agent, and dispersing again to prepare a sample suspension; and detecting the granularity of the fluticasone propionate in the obtained sample suspension by adopting a laser diffraction method. The invention provides a method suitable for detecting the granularity of raw materials in a suspension for fluticasone propionate aerosol inhalation, the suspension for fluticasone propionate aerosol inhalation is subjected to water bath heating, so that auxiliary materials are dissolved, it is guaranteed that only the fluticasone propionate raw material exists in a sample, the problem of interference of the auxiliary materials in detection of the granularity of the raw materials is avoided, and the detection accuracy of the granularity of the raw materials is improved. The accurate detection of the particle size distribution of the fluticasone propionate raw material in the suspension is realized.

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

The invention relates to the related technical field of measurement of the content of fluticasone propionate emulsifiable paste, in particular to a method for detecting the content of paste by adopting a high performance liquid chromatography, and particularly relates to a method for measuring the content of fluticasone propionate emulsifiable paste by adopting the high performance liquid chromatography, in particular to a method for detecting the content of fluticasone propionate emulsifiable paste by adopting the high performance liquid chromatography. Comprising the following steps: preparing a mobile phase from a diammonium hydrogen phosphate buffer solution (the pH value is 2.0-5.0), methanol and acetonitrile by adopting an octadecyl silane bonded silica gel column; and carrying out isocratic elution. According to the method disclosed by the invention, the diammonium hydrogen phosphate buffer solution-methanol-acetonitrile with a specific ratio is adopted as a mobile phase, and a chromatographic system in which an octadecyl silane bonded silica gel column and a guard column are connected in series is combined, so that the interference of oily auxiliary materials in a cream matrix is effectively eliminated, and the detection specificity and the separation effect are remarkably improved; besides, key chromatographic parameters such as column temperature, flow velocity and detection wavelength are optimized, and a scientific test sample pretreatment process is matched, so that the accuracy and reliability of a content measurement result are guaranteed.

The invention provides a method for detecting the content of fluticasone propionate cream. The method comprises the following steps: preparing an internal standard substance solution, preparing a test solution, preparing a reference substance solution, detecting and analyzing. According to the method, the cream is dispersed by heating in a water bath, the problem of uneven dissolution of the cream is solved, and the solution is centrifuged and filtered in a low-temperature environment of 6-10 DEG C to remove matrix impurities, so that the treatment efficiency of a cream sample can be improved, and the influence of personnel operation on a detection result can be effectively reduced; the accuracy of a detection result is improved. Besides, heptyl 4-hydroxybenzoate is selected as an internal standard substance, the retention behavior of heptyl 4-hydroxybenzoate is matched with that of fluticasone propionate, the solubility of heptyl 4-hydroxybenzoate in 65% ethanol is consistent, matrix adsorption and extraction errors can be effectively corrected, and the accuracy and reproducibility are remarkably superior to those of an existing method.

A composition of fluticasone / linezolid-loaded nanodiamond / polyacrylonitrile nanofibers, consisting of: • Fluticasone propionate in a quantity of 25 mg to 100 mg; • Linezolid in a quantity of 25 mg to 100 mg; • Nanodiamonds dispersed in a concentration of approximately 1 mg / ml dimethylformamide (DMF); and • a polyacrylonitrile (PAN) polymer matrix prepared as a 10% w / v solution in DMF, wherein the drugs, nanodiamonds and PAN are uniformly combined to form an electrospinnable nanocomposite solution, and electrospinning is carried out under conditions suitable for producing nanofibers with controlled drug release, porosity and structural integrity for wound healing applications.

The invention discloses a photothermal stable fluticasone propionate emulsifiable paste preparation and a preparation process thereof, and relates to the technical field of external emulsifiable paste. Comprising the following steps: step 1, (1) adding isopropyl myristate and cetostearyl alcohol into liquid paraffin, mixing, heating and stirring to obtain an oil phase; (2) adding citric acid, sodium citrate, imidazolidinyl urea, a photo-thermal stabilizer and polyethylene glycol hexadecyl-octadecyl ether into deionized water, mixing, heating and stirring to obtain a water phase; (3) adding fluticasone propionate and propylene glycol into deionized water, heating and stirring to obtain a fluticasone propionate solution; and 2, adding the water phase into the oil phase, stirring, adding a fluticasone propionate solution, uniformly mixing, adding propyl hydroxybenzoate and methyl hydroxybenzoate, and standing at room temperature to obtain the fluticasone propionate emulsifiable paste preparation. The fluticasone propionate emulsifiable paste preparation prepared by the invention has good photo-thermal stability and meets the requirements of external emulsifiable paste.

The present application provides a kind of detection method of fluticasone propionate bulk drug particle size, the method is first used to high-power ultrasonic dispersion medium break dispersion medium molecule aggregation, then lower power ultrasonic dispersion system is stabilized, avoid dispersing agent itself aggregation to bulk drug particle is wrapped, form measurement error.In addition, by intermittent electric field, so that particle produces relative displacement or oscillation, while applying ultrasonic dissociation agglomerate, realize the complete wetting of bulk drug particle, stable dispersion and accurate detection, the method is lower to instrument requirement, can realize the accurate detection of strong hydrophobicity bulk drug particle size in the case where not increasing detection cost and detection time.

This invention relates to fluticasone propionate cream, belonging to the field of topical pharmaceutical preparations. By using a mixed solvent of hexanediol and propylene glycol, along with a composite stabilizer, this invention solves the problem in existing fluticasone propionate creams where inappropriate intradermal retention leads to insufficient therapeutic efficacy. Simultaneously, it ensures the stability of the cream; the cream of this invention remains stable under high temperature, high temperature, light, low temperature, and freeze-thaw conditions, with no significant increase in related substances. The preparation process of the fluticasone propionate cream of this invention is simple and suitable for industrial production.

The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

The application belongs to the technical field of mother liquor recycling, and particularly relates to a treatment method of fluticasone propionate mother liquor. The treatment method of fluticasone propionate mother liquor provided by the application first mixes the fluticasone propionate mother liquor and amine compounds to perform a Hofmann alkylation reaction, quenches fluorohalomethane under mild conditions by using the Hofmann alkylation reaction of the amine compounds, reduces the impurity of fluticasone propionate, and recovers fluticasone propionate with high purity and high recovery rate, so that the material is fully utilized, and the pollution of fluorohalomethane and steroid compounds (fluticasone propionate) to the environment is reduced.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a suspension for fluticasone propionate aerosol inhalation and a preparation method thereof. The suspension for fluticasone propionate aerosol inhalation provided by the invention is prepared from fluticasone propionate, isooctanol phosphate, a stabilizer, sodium dihydrogen phosphate, disodium hydrogen phosphate and an osmotic pressure regulator. According to the suspension for the fluticasone propionate aerosol inhalation provided by the invention, the foaming amount of the suspension is obviously reduced and the content uniformity of the suspension is improved by replacing the surfactant with the isooctanol phosphate, so that the product quality of the suspension for the fluticasone propionate aerosol inhalation is ensured.

The invention provides a fluticasone furoate micellar solution. The fluticasone furoate micellar solution comprises fluticasone furoate, a lipophilic component and a nonionic surfactant. According to the fluticasone furoate pharmaceutical composition, the dissolution rate and the absorption rate of fluticasone furoate on nasal mucosa and alveolar mucosa can be remarkably improved, and the administration dosage can be further reduced while the same curative effect is obtained, so that the toxic and side effects are reduced. The aerosol inhalation powder is especially suitable for aerosol inhalation, can provide better pulmonary deposition, and is especially suitable for nasal administration to reduce the administration dosage and improve the bioavailability.

This invention relates to a method of treatment of asthma comprising a pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients, wherein the fluticasone propionate is administered at a delivered dose of 22-59 mcg per inhalation and the albuterol sulfate is administered at a delivered dose of 92-124 mcg per inhalation, and wherein the treatment provides an improved baseline-adjusted postdose forced expiratory volume in one second (FEV1) area under the effect curve from time zero to 6 hours (AUEC0-6h) when compared to fluticasone propionate treatment and an improved baseline-adjusted trough FEV1 when compared to albuterol sulfate treatment.

This invention relates to the field of antiviral drug technology, disclosing fluticasone propionate and its application in the preparation of drugs against CHIKV and EEEV. Fluticasone propionate acts on the later stages of the CHIKV and EEEV life cycle. This invention is the first to demonstrate that fluticasone propionate has significant antiviral activity against CHIKV and EEEV, filling the gap in the lack of specific treatments for these two viruses. Furthermore, the fluticasone propionate of this invention is an already marketed drug; repurposing this existing drug can significantly shorten the research and development cycle and is expected to enable rapid clinical application.

The invention discloses a fluticasone propionate suspension nasal spray which is prepared by the following steps: on the basis of a prescription of fluticasone propionate micro powder, a suspending aid microcrystalline cellulose sodium carboxymethyl cellulose, an osmotic pressure regulator, a wetting agent and water, using a stabilizer methyl glucitol polyether-20 and hexanediol; the problem that the container adsorbs the fluticasone propionate micro powder in the preparation process is solved, and meanwhile degradation and particle size increase of the fluticasone propionate are effectively controlled.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

The utility model relates to the technical field of cream packaging, provides an applicator for fluticasone propionate cream, and solves the technical problems that the fluticasone propionate cream is poor in flowability and poor in ball bottle using effect. The applicator comprises a bottle cap with a rolling body and a hard bottle body, a cream pushing assembly is arranged in the hard bottle body, and the applicator is characterized in that the cream pushing assembly comprises a pushing plate and a linear driving structure; the applicator further comprises an extrusion assembly. The extrusion assembly comprises an inner corrugated compression body, a perforated plate and an outer corrugated compression body, the inner corrugated compression body and the perforated plate are arranged between the lead screw and the bottle body in a sleeving mode, the upper end and the lower end of the inner corrugated compression body are fixedly connected with the push plate and the perforated plate respectively, and the linear driving structure is used for driving the push plate to move up and down along the bottle body.

The invention relates to a buffered aqueous composition comprising fluticasone propionate dissolved therein in a concentration of at least 20 µg / mL, wherein the composition further comprises a saponin component selected from the group consisting of escin, glycyrrhizin, and Quillaja saponaria extract, a buffer adjusted to a pH of from 4 to 8; and the surfactant poloxamer P407 in a con- centration of from 2.5 to 15 %w / v. The invention further relates to the use of the composition in the treatment of inflammatory and / or allergic conditions of the human body.